Zoetis Inc.

ZTSSEC EDGAR

Pharmaceutical PreparationsCIK: 1555280

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$8.5B	$8.1B	$7.8B	$6.7B	$6.3B
Cost of Goods and Services Sold	$2.6B	$2.5B	$2.3B	$2.1B	$2.0B
Selling, General and Administrative Expense	$2.2B	$2.0B	$2.0B	$1.7B	$1.6B
Interest Expense	$239.0M	$221.0M	$224.0M	$231.0M	$223.0M
Nonoperating Income (Expense)	$159.0M	-$40.0M	-$48.0M	-$17.0M	$57.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$2.9B	$2.7B	$2.5B	$2.0B	$1.8B
Income Tax Expense (Benefit)	$596.0M	$545.0M	$454.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$14.2B	$14.3B	$14.9B	$13.9B	$13.6B
Assets, Current	$6.0B	$6.3B	$7.5B	$6.9B	$6.6B
Cash and Cash Equivalents, at Carrying Value	—	—	—	—	—
Accounts Receivable, after Allowance for Credit Loss, Current	$1.3B	$1.3B	$1.2B	$1.1B	$1.0B
Inventory, Net	$2.3B	$2.6B	$2.3B	$1.9B	$1.6B
Liabilities	$9.5B	$9.3B	$10.5B	$9.4B	$9.8B
Liabilities, Current	$3.4B	$1.9B	$3.2B	$1.8B	$2.2B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$2.4B	$1.9B	$2.2B	$2.1B	$1.8B
Net Cash Provided by (Used in) Investing Activities	-$777.0M	-$883.0M	-$458.0M	-$572.0M	-$504.0M
Net Cash Provided by (Used in) Financing Activities	-$3.1B	-$904.0M	-$1.9B	$123.0M	-$951.0M
Payments to Acquire Property, Plant, and Equipment	$732.0M	$586.0M	$477.0M	$453.0M	$460.0M
Payments for Repurchase of Common Stock	$1.1B	$1.6B	$743.0M	$250.0M	$626.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)